GLP1R and Insulin resistance: Cotadutide exerts a unique dual agonism mode of action upon the glucose and lipid metabolism that appears to be superior compared with GLP-1 agonism alone, given the indirect effects of reduced inflammation and reversed fibrosis found in preclinical models, in addition to significant properties to induce HbA1c and weight reduction and to improve insulin resistance [109].